BioStem Technologies posts Q2 2026 revenue growth, completes Nasdaq uplisting

BioStem Technologies, Inc. reported financial results for the quarter ended June 30, 2026 on August 12, 2026. The company said it completed the uplisting of its common stock to the Nasdaq Capital Market on August 7, 2026, and closed a $2.5 million private placement with its first institutional investor.¹

On the commercial side, BioStem said it continued to scale its commercial organization by expanding the direct sales force, integrating CRM and ERP systems, and transitioning major group purchasing organization agreements to broaden hospital access.¹ The company also said it issued eight new U.S. design patents covering fenestrated human placental allograft technology.¹

Net revenue for the quarter was $7.9 million, compared to $6.1 million in the first quarter of 2026 and $11.0 million in the second quarter of 2025.¹ Growth was primarily driven by Neox® and Clarix® product sales.¹

For the full year, BioStem raised its 2026 revenue guidance to a range of $26 million to $29 million, up from its prior guidance of $25 million to $29 million.¹

On cash, the company reported that cash and cash equivalents totaled $7.0 million as of June 30, 2026, down from $13.7 million at the end of the first quarter of 2026, with cash used in operations of $5.5 million during the quarter.¹ BioStem also said that during the quarter it closed a $2.5 million private financing and resolved $5.3 million in outstanding debt through a $3.5 million cash payment and the issuance of a $1.0 million promissory note.¹

The release did not state a specific cash runway figure beyond these disclosures.